Aurora Spine was issued its second U.S. Patent No. 11,850,162, Body Density Scan Result-Matched Orthopedic Implants and Methods of Use for DEXA Patient-Matched Implant Technology.
Aurora Spine’s first-of-its kind DEXA Technology is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support. This patent will be used to create implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable outcome based on that patient’s bone density.
In 2022, the company launched its first DEXA Technology-based product, the DEXA-C interbody spacer line for anterior cervical fusion.
“Aurora Spine’s first in the world and first to market DEXA Technology based implant provides surgeons with the choice in selecting the matching density implant for their patient,” said Trent Northcutt, President & CEO of Aurora Spine. “Aurora’s second patent for bone quality-matching implants strengthens the Company’s intellectual property portfolio significantly. Our proprietary DEXA Technology represents our continued commitment to delivering best-in-class implants that enable our surgeon partners to overcome common osteoporosis challenges faced in traditional procedures.”
Aurora Spine was issued its second U.S. Patent No. 11,850,162, Body Density Scan Result-Matched Orthopedic Implants and Methods of Use for DEXA Patient-Matched Implant Technology.
Aurora Spine’s first-of-its kind DEXA Technology is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure...
Aurora Spine was issued its second U.S. Patent No. 11,850,162, Body Density Scan Result-Matched Orthopedic Implants and Methods of Use for DEXA Patient-Matched Implant Technology.
Aurora Spine’s first-of-its kind DEXA Technology is designed to match a patient’s bone density, promote bone in-growth while maintaining the biomechanical structure and bone support. This patent will be used to create implants that match the patient’s specific bone density based on a DEXA Scan/T-score allowing for the best bone fusion treatment and most favorable outcome based on that patient’s bone density.
In 2022, the company launched its first DEXA Technology-based product, the DEXA-C interbody spacer line for anterior cervical fusion.
“Aurora Spine’s first in the world and first to market DEXA Technology based implant provides surgeons with the choice in selecting the matching density implant for their patient,” said Trent Northcutt, President & CEO of Aurora Spine. “Aurora’s second patent for bone quality-matching implants strengthens the Company’s intellectual property portfolio significantly. Our proprietary DEXA Technology represents our continued commitment to delivering best-in-class implants that enable our surgeon partners to overcome common osteoporosis challenges faced in traditional procedures.”
Copy to clipboard 
